Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aprea TherapeuticsAPRE -2.04%30 3-Year EBITDA Growth Rate is 55.20% as of Mar. 2026, which is 17% above its 10-year median of 47.00. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,136 Biotechnology companies, Aprea Therapeutics ranks better than 88.56% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 55.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 51.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aprea Therapeutics was 58.00% per year. The lowest was -30.30% per year. And the median was 47.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aprea Therapeutics 3-Year EBITDA Growth Rate Related Terms
APRE vs SYBX, MTVA, CNSP: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Aprea Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprea Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aprea Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 55.20% mean?
Aprea Therapeutics (APRE) has a 3-Year EBITDA Growth Rate of 55.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aprea Therapeutics and its competitors. This is 17% above median its historical median of 47.00. According to the industry distribution chart, Aprea Therapeutics ranks #130 out of 1136 companies in the Biotechnology industry, placing it in the top 11.4%.
Is Aprea Therapeutics' 3-Year EBITDA Growth Rate too high?
Aprea Therapeutics' current 3-Year EBITDA Growth Rate of 55.20% is 17% above median its 10-year median of 47.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Aprea Therapeutics' value of 55.20% is 271.7% above this industry median. Based on the distribution chart, Aprea Therapeutics ranks #130 out of 1136 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' 3-Year EBITDA Growth Rate compare to SYBX and MTVA?
According to the Biotechnology industry distribution chart, Aprea Therapeutics ranks #130 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Aprea Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Aprea Therapeutics' value of 55.20% is 271.7% above this benchmark. While the company's 10-year median is 47.00 vs. the industry median of 14.85, Aprea Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aprea Therapeutics's current 3-Year EBITDA Growth Rate of 55.20% is 271.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aprea Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprea Therapeutics's current 3-Year EBITDA Growth Rate is 55.20%, which is 17% above median its own 10-year median of 47.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current 3-Year EBITDA Growth Rate of 55.20%. The current 3-Year EBITDA Growth Rate is 55.20%, which is 17% above median its 10-year median of 47.00 and 271.7% above the Biotechnology industry median of 14.85. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current 3-Year EBITDA Growth Rate is 55.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score
Get the complete analysis for APRE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APRE has been successfully added to your 
